> top > docs > PMC:1064895 > spans > 20649-21991 > annotations

PMC:1064895 / 20649-21991 JSONTXT

Annnotations TAB JSON ListView MergeView

test3

Id Subject Object Predicate Lexical cue
T15581 1305-1314 Positive_regulation denotes activated
T15580 1291-1301 Gene_expression denotes production
T15579 1285-1290 Protein denotes IL-17
T15578 1190-1194 Protein denotes CD28
T15577 1120-1124 Protein denotes AP-1
T15576 1048-1053 Protein denotes IκB-α
T15575 1033-1044 Protein_catabolism denotes degradation
T15574 1019-1029 Negative_regulation denotes inhibition
T15573 1006-1011 Protein denotes IκB-α
T15572 959-964 Protein denotes IL-17
T15571 935-942 Binding denotes binding
T15570 919-924 Negative_regulation denotes block
T15569 697-701 Protein denotes CD28
T15568 578-583 Protein denotes c-Rel
T15567 551-554 Protein denotes p50
T15566 543-546 Protein denotes p65
T15565 432-437 Protein denotes IL-17
T15564 412-419 Binding denotes binding
T15563 402-411 Positive_regulation denotes increased
T15562 375-379 Protein denotes CD28
T15561 282-287 Protein denotes IL-17
T15560 163-173 Gene_expression denotes expression
T15559 157-162 Protein denotes IL-17
T15558 148-156 Negative_regulation denotes inducing
T15557 121-126 Protein denotes IL-15
T15556 113-116 Protein denotes PHA
T15555 91-95 Protein denotes CD28
T15551 1285-1290 Protein denotes IL-17
T15550 1190-1194 Protein denotes CD28
T15549 1120-1124 Protein denotes AP-1
T15548 1048-1053 Protein denotes IκB-α
T15547 1006-1011 Protein denotes IκB-α
T15546 959-964 Protein denotes IL-17
T15545 697-701 Protein denotes CD28
T15544 578-583 Protein denotes c-Rel
T15543 551-554 Protein denotes p50
T15542 543-546 Protein denotes p65
T15541 432-437 Protein denotes IL-17
T15540 375-379 Protein denotes CD28
T15539 282-287 Protein denotes IL-17
T15538 157-162 Protein denotes IL-17
T15537 121-126 Protein denotes IL-15
T15536 113-116 Protein denotes PHA
T15535 91-95 Protein denotes CD28
R8555 T15556 T15558 causeOf PHA,inducing
R8556 T15559 T15560 themeOf IL-17,expression
R8557 T15560 T15558 themeOf expression,inducing
R8558 T15564 T15563 themeOf binding,increased
R8559 T15571 T15570 themeOf binding,block
R8560 T15575 T15574 themeOf degradation,inhibition
R8561 T15576 T15574 themeOf IκB-α,inhibition
R8562 T15576 T15575 themeOf IκB-α,degradation
R8563 T15579 T15580 themeOf IL-17,production

BioNLP16_Messiy

Id Subject Object Predicate Lexical cue
T16333 1285-1290 Protein denotes IL-17
T16342 1291-1301 Gene_expression denotes production
T16341 1019-1029 Negative_regulation denotes inhibition
T16340 1033-1044 Protein_catabolism denotes degradation
T16339 412-419 Binding denotes binding
T16338 402-411 Positive_regulation denotes increased
T16337 148-156 Positive_regulation denotes inducing
T16336 59-68 Positive_regulation denotes activated
T16335 163-173 Gene_expression denotes expression
T16332 1190-1194 Protein denotes CD28
T16331 1120-1124 Protein denotes AP-1
T16330 1048-1053 Protein denotes IκB-α
T16329 1006-1011 Protein denotes IκB-α
T16328 959-964 Protein denotes IL-17
T16327 697-701 Protein denotes CD28
T16326 578-583 Protein denotes c-Rel
T16325 551-554 Protein denotes p50
T16324 543-546 Protein denotes p65
T16323 375-379 Protein denotes CD28
T16322 432-437 Protein denotes IL-17
T16321 282-287 Protein denotes IL-17
T16320 157-162 Protein denotes IL-17
T16319 121-126 Protein denotes IL-15
T16318 113-116 Protein denotes PHA
T16317 91-95 Protein denotes CD28
R8862 T16318 T16336 themeOf PHA,activated
R8863 T16319 T16336 causeOf IL-15,activated
R8864 T16320 T16335 themeOf IL-17,expression
R8865 T16322 T16339 themeOf IL-17,binding
R8866 T16330 T16340 themeOf IκB-α,degradation
R8867 T16333 T16342 themeOf IL-17,production
R8868 T16335 T16337 themeOf expression,inducing
R8869 T16339 T16338 themeOf binding,increased
R8870 T16340 T16341 themeOf degradation,inhibition

BioNLP16_DUT

Id Subject Object Predicate Lexical cue
T16808 1291-1301 Gene_expression denotes production
T16807 1019-1029 Negative_regulation denotes inhibition
T16806 1033-1044 Protein_catabolism denotes degradation
T16805 919-924 Negative_regulation denotes block
T16804 412-419 Binding denotes binding
T16803 148-156 Positive_regulation denotes inducing
T16802 163-173 Gene_expression denotes expression
T16800 1285-1290 Protein denotes IL-17
T16799 1190-1194 Protein denotes CD28
T16798 1120-1124 Protein denotes AP-1
T16797 1048-1053 Protein denotes IκB-α
T16796 1006-1011 Protein denotes IκB-α
T16795 959-964 Protein denotes IL-17
T16794 697-701 Protein denotes CD28
T16793 578-583 Protein denotes c-Rel
T16792 551-554 Protein denotes p50
T16791 543-546 Protein denotes p65
T16790 375-379 Protein denotes CD28
T16789 432-437 Protein denotes IL-17
T16788 282-287 Protein denotes IL-17
T16787 157-162 Protein denotes IL-17
T16786 121-126 Protein denotes IL-15
T16785 113-116 Protein denotes PHA
T16784 91-95 Protein denotes CD28
R9192 T16787 T16802 themeOf IL-17,expression
R9193 T16789 T16804 themeOf IL-17,binding
R9194 T16795 T16805 themeOf IL-17,block
R9195 T16797 T16806 themeOf IκB-α,degradation
R9196 T16800 T16808 themeOf IL-17,production
R9197 T16802 T16803 themeOf expression,inducing
R9198 T16806 T16807 themeOf degradation,inhibition

biosemtest

Id Subject Object Predicate Lexical cue
T15816 966-971 UMLS/C1825592 denotes romot
T15815 435-440 UMLS/C1825592 denotes 17 pr
T15814 284-289 UMLS/C1825592 denotes -17.
T15813 158-163 UMLS/C1825592 denotes L-17
T15811 1257-1261 UMLS/C0024497 denotes llul
T15788 312-328 UMLS/C1518434 denotes clear extracts f
T15787 478-486 UMLS/C0332298 denotes trols (l
T15786 770-774 UMLS/C1517892 denotes bet
T15785 149-157 UMLS/C0205263 denotes nducing
T15784 1191-1195 UMLS/C0332287 denotes D28
T15783 691-695 UMLS/C0332287 denotes ant
T15782 367-371 UMLS/C0332287 denotes us a
T15781 82-86 UMLS/C0332287 denotes lus
T15780 1042-1053 UMLS/C0243125 denotes on of IκB-α
T15779 546-549 UMLS/C1335610 denotes an
T15778 851-858 UMLS/C0243122 denotes g activ
T15777 414-421 UMLS/C0243122 denotes nding o
T15776 600-606 UMLS/C2347086 denotes mal PB
T15775 918-924 UMLS/C1521826 denotes block
T15774 1257-1261 UMLS/C0205225 denotes llul
T15773 1028-1038 UMLS/C1628982 denotes n of degra
T15772 404-413 UMLS/C0205217 denotes creased b
T15771 1093-1097 UMLS/C1692345 denotes Fig.
T15770 616-620 UMLS/C1692345 denotes e pa
T15769 510-515 UMLS/C0005507 denotes ay de
T15768 223-228 UMLS/C0005507 denotes ssay
T15767 1098-1102 UMLS/C1704250 denotes 7c).
T15766 600-606 UMLS/C0439166 denotes mal PB
T15765 1327-1331 UMLS/C1321301 denotes tien
T15764 739-743 UMLS/C1321301 denotes (Fi
T15763 607-611 UMLS/C1321301 denotes C th
T15762 337-341 UMLS/C1321301 denotes MC s
T15761 950-958 UMLS/C0439167 denotes y in the
T15760 859-867 UMLS/C0439167 denotes ty after
T15759 788-796 UMLS/C0439167 denotes vity and
T15758 546-549 UP/P48018 denotes an
T15757 1136-1143 UMLS/C1704259 denotes not ac
T15755 478-486 UMLS/C0243148 denotes trols (l
T15754 1207-1211 UMLS/C1511726 denotes own)
T15753 822-826 UMLS/C0596608 denotes to d
T15752 230-234 UMLS/C0596608 denotes MSA)
T15751 554-557 UMLS/C1539081 denotes (l
T15750 537-542 UMLS/C0439645 denotes ds in
T15749 1257-1261 UMLS/C1542147 denotes llul
T15748 546-549 UMLS/C1420556 denotes an
T15747 1276-1293 UMLS/C0037080 denotes thway in IL-17 pr
T15746 42-59 UMLS/C0037080 denotes ignaling pathway
T15745 581-586 UMLS/C0035018 denotes el (l
T15744 246-257 UMLS/C0524637 denotes cognition s
T15743 1131-1135 UP/P21525 denotes y wa
T15741 546-549 UMLS/C0599933 denotes an
T15740 783-787 UMLS/C1705325 denotes act
T15739 633-641 UMLS/C1441672 denotes erved, b
T15738 478-486 UMLS/C1547100 denotes trols (l
T15737 770-774 UMLS/C0208973 denotes bet
T15736 851-858 UMLS/C1689898 denotes g activ
T15735 414-421 UMLS/C1689898 denotes nding o
T15734 651-657 UMLS/C0449286 denotes ree of
T15733 600-606 UMLS/C1873497 denotes mal PB
T15732 546-549 UP/P21521 denotes an
T15731 950-958 UMLS/C0441655 denotes y in the
T15730 859-867 UMLS/C0441655 denotes ty after
T15729 788-796 UMLS/C0441655 denotes vity and
T15728 1028-1038 UMLS/C0021467 denotes n of degra
T15727 1028-1038 UMLS/C0021469 denotes n of degra
T15726 1262-1275 UMLS/C0178719 denotes r signaling p
T15725 28-41 UMLS/C0178719 denotes ntracellular
T15724 1104-1107 UMLS/C0349966 denotes n c
T15723 982-985 UMLS/C0349966 denotes ).
T15722 745-748 UMLS/C0349966 denotes 7b
T15721 303-306 UMLS/C0349966 denotes g.
T15720 1131-1135 UP/A8MPH9 denotes y wa
T15718 404-413 UMLS/C0442805 denotes creased b
T15717 404-413 UMLS/C0442808 denotes creased b
T15716 1098-1102 UMLS/C0449243 denotes 7c).
T15715 822-826 UMLS/C0949632 denotes to d
T15714 230-234 UMLS/C0949632 denotes MSA)
T15713 454-464 UMLS/C1707455 denotes parison wi
T15712 1098-1102 UMLS/C0040223 denotes 7c).
T15711 478-486 UMLS/C1550141 denotes trols (l
T15710 537-542 UMLS/C0185014 denotes ds in
T15709 529-536 UMLS/C0333051 denotes fted ba
T15708 918-924 UMLS/C1254351 denotes block
T15707 1131-1135 UMLS/C0087140 denotes y wa
T15705 651-657 UMLS/C0542560 denotes ree of
T15704 258-263 UMLS/C1546778 denotes tes i
T15703 122-127 UMLS/C1149222 denotes L-15,
T15701 114-117 UMLS/C0030779 denotes HA
T15700 758-765 UMLS/C1446409 denotes irm the
T15699 651-657 UMLS/C0441889 denotes ree of
T15698 546-549 UP/P47191 denotes an
T15697 4-15 UMLS/C1292732 denotes nvestigate
T15696 122-127 UMLS/C0254610 denotes L-15,
T15695 164-174 UMLS/C0185117 denotes xpression,
T15694 510-515 UMLS/C1510438 denotes ay de
T15693 223-228 UMLS/C1510438 denotes ssay
T15692 621-628 UMLS/C0449774 denotes tern wa
T15691 554-557 UP/P83939 denotes (l
T15690 1317-1326 UMLS/C1879547 denotes MC from p
T15689 1152-1161 UMLS/C1879547 denotes y stimula
T15688 668-678 UMLS/C1879547 denotes vation by
T15687 60-69 UMLS/C1879547 denotes ctivated
T15685 122-127 UMLS/C1334105 denotes L-15,
T15684 258-263 UMLS/C2347790 denotes tes i
T15683 1131-1135 UMLS/C0162508 denotes y wa
T15681 554-557 UMLS/C1417708 denotes (l
T15680 868-883 UMLS/C0001758 denotes treatment with
T15679 133-144 UMLS/C1273518 denotes esponsible
T15678 1131-1135 UMLS/C1333571 denotes y wa
T15676 1165-1176 UMLS/C1948023 denotes with anti-
T15675 342-352 UMLS/C1948023 denotes imulated w
T15674 992-1008 UMLS/C0005863 denotes blotting for Iκ
T15673 478-486 UMLS/C0009932 denotes trols (l
T15672 783-787 UP/P42336 denotes act
T15671 812-821 UMLS/C0884358 denotes rmed EMSA
T15670 179-188 UMLS/C0884358 denotes erformed
T15669 992-1008 UMLS/C0949466 denotes blotting for Iκ
T15668 1042-1053 UMLS/C0699900 denotes on of IκB-α
T15667 1068-1076 UMLS/C0251991 denotes d PDTC a
T15666 894-902 UMLS/C0251991 denotes 02 and P
T15665 966-971 UMLS/C1522571 denotes romot
T15664 435-440 UMLS/C1522571 denotes 17 pr
T15663 284-289 UMLS/C1522571 denotes -17.
T15662 158-163 UMLS/C1522571 denotes L-17
T15660 1165-1176 UMLS/C1292856 denotes with anti-
T15659 1081-1085 UMLS/C0084183 denotes sam
T15658 907-911 UMLS/C0084183 denotes Both
T15657 1262-1275 UMLS/C0175996 denotes r signaling p
T15656 28-41 UMLS/C0175996 denotes ntracellular
T15655 918-924 UMLS/C0450442 denotes block
T15654 966-971 UMLS/C0384648 denotes romot
T15653 435-440 UMLS/C0384648 denotes 17 pr
T15652 284-289 UMLS/C0384648 denotes -17.
T15651 158-163 UMLS/C0384648 denotes L-17
T15649 950-958 UMLS/C1561536 denotes y in the
T15648 859-867 UMLS/C1561536 denotes ty after
T15647 788-796 UMLS/C1561536 denotes vity and
T15646 164-174 UMLS/C0017262 denotes xpression,
T15645 783-787 UMLS/C1368105 denotes act
T15644 812-821 UMLS/C1550369 denotes rmed EMSA
T15643 179-188 UMLS/C1550369 denotes erformed
T15642 830-839 UMLS/C0521095 denotes mine the
T15641 925-930 UMLS/C0332206 denotes NF-κB
T15640 758-765 UMLS/C0521093 denotes irm the
T15639 925-930 UMLS/C1706084 denotes NF-κB
T15638 1098-1102 UMLS/C1548318 denotes 7c).
T15637 258-263 UMLS/C0205145 denotes tes i
T15636 510-515 UMLS/C0243073 denotes ay de
T15635 223-228 UMLS/C0243073 denotes ssay
T15634 758-765 UMLS/C1456348 denotes irm the
T15633 1276-1293 UMLS/C0086982 denotes thway in IL-17 pr
T15632 42-59 UMLS/C0086982 denotes ignaling pathway
T15631 851-858 UMLS/C1167622 denotes g activ
T15630 414-421 UMLS/C1167622 denotes nding o
T15629 925-930 UMLS/C1533157 denotes NF-κB
T15628 966-971 UMLS/C1623218 denotes romot
T15627 435-440 UMLS/C1623218 denotes 17 pr
T15626 284-289 UMLS/C1623218 denotes -17.
T15625 158-163 UMLS/C1623218 denotes L-17
T15623 554-557 UP/Q05894 denotes (l
T15622 651-657 UMLS/C1561545 denotes ree of
T15621 554-557 UP/P23061 denotes (l
T15620 308-310 UMLS/C1553639 denotes ,
T15619 1098-1102 UMLS/C1547403 denotes 7c).
T15618 1098-1102 UMLS/C1632851 denotes 7c).
T15617 600-606 UMLS/C1704701 denotes mal PB
T15616 98-112 UMLS/C0009630 denotes oncanavalin A,
T15615 643-646 UMLS/C0005341 denotes th
T15614 783-787 UMLS/C0285761 denotes act
T15613 546-549 UP/P41823 denotes an
T15612 827-829 UMLS/C0319022 denotes te
T15611 755-757 UMLS/C0319022 denotes on
T15610 432-434 UMLS/C0319022 denotes IL
T15609 1-3 UMLS/C0319022 denotes o
T15608 1098-1102 UMLS/C0392761 denotes 7c).
T15607 925-930 UMLS/C0028778 denotes NF-κB
T15606 600-606 UMLS/C1550457 denotes mal PB
T15605 925-930 UMLS/C0233660 denotes NF-κB
T15604 972-980 UMLS/C0086860 denotes r (Fig.
T15603 441-450 UMLS/C0086860 denotes moters in
T15602 271-280 UMLS/C0086860 denotes omoters o
T15601 1131-1135 UMLS/C0812312 denotes y wa
T15599 758-765 UMLS/C0750484 denotes irm the
T15598 258-263 UMLS/C1515974 denotes tes i
T15597 851-858 UMLS/C1145667 denotes g activ
T15596 414-421 UMLS/C1145667 denotes nding o
T15595 1093-1097 UMLS/C0445247 denotes Fig.
T15594 616-620 UMLS/C0445247 denotes e pa
T15593 600-606 UMLS/C1551394 denotes mal PB
T15592 851-858 UMLS/C2349209 denotes g activ
T15591 414-421 UMLS/C2349209 denotes nding o
T15590 715-722 UMLS/C0522510 denotes nse tha
T15589 1131-1135 UMLS/C0085828 denotes y wa
T15586 554-557 UMLS/C1705525 denotes (l
T15585 1117-1125 UMLS/C1979874 denotes he AP-1
T15584 478-486 UMLS/C1882979 denotes trols (l
T15583 938-949 UMLS/C1148673 denotes ding activi
T15582 770-774 UMLS/C1704666 denotes bet
T15810 1297-1313 UMLS/C1819444 denotes tion by activate
T15809 554-557 UP/Q28618 denotes (l
T15808 478-486 UMLS/C2587213 denotes trols (l
T15807 918-924 UMLS/C1551364 denotes block
T15806 529-536 UMLS/C2347509 denotes fted ba
T15805 546-549 UP/P21707 denotes an
T15804 537-542 UMLS/C0175723 denotes ds in
T15803 600-606 UMLS/C0205307 denotes mal PB
T15802 546-549 UP/P46096 denotes an
T15801 546-549 UP/P21579 denotes an
T15800 651-657 UMLS/C2348088 denotes ree of
T15799 1136-1143 UMLS/C1705987 denotes not ac
T15797 783-787 UMLS/C1150481 denotes act
T15796 1212-1215 UMLS/C1518422 denotes de
T15795 1148-1151 UMLS/C1518422 denotes ed
T15794 574-577 UMLS/C1518422 denotes in
T15793 588-592 UMLS/C1708639 denotes e 5)
T15792 559-564 UMLS/C1708639 denotes es 3
T15791 488-492 UMLS/C1708639 denotes e 1)
T15790 383-387 UMLS/C1708639 denotes ne 2
T15789 114-117 UMLS/C0031858 denotes HA

pmc-enju-pas

Id Subject Object Predicate Lexical cue
T16026 648-654 NN denotes degree
T16025 644-647 DT denotes the
T16024 640-643 CC denotes but
T16023 638-639 -COMMA- denotes ,
T16022 630-638 VB denotes observed
T16021 626-629 VB denotes was
T16020 618-625 NN denotes pattern
T16019 613-617 JJ denotes same
T16018 609-612 DT denotes the
T16017 604-608 NN denotes PBMC
T16016 597-603 JJ denotes normal
T16015 594-596 IN denotes In
T16014 591-592 -RRB- denotes )
T16013 590-591 CD denotes 5
T16012 585-589 NN denotes lane
T16011 584-585 -LRB- denotes (
T16010 578-583 NN denotes c-Rel
T16009 575-577 IN denotes in
T16008 571-574 RB denotes not
T16007 569-570 -RRB- denotes )
T16006 568-569 CD denotes 4
T16005 564-567 CC denotes and
T16004 562-563 CD denotes 3
T16003 556-561 NN denotes lanes
T16002 555-556 -LRB- denotes (
T16001 551-554 NN denotes p50
T16000 547-550 CC denotes and
T15999 543-546 NN denotes p65
T15998 540-542 IN denotes in
T15997 534-539 NN denotes bands
T15996 526-533 VB denotes shifted
T15995 513-525 VB denotes demonstrated
T15994 507-512 NN denotes assay
T15993 496-506 NN denotes supershift
T15992 494-495 DT denotes A
T15991 491-492 -RRB- denotes )
T15990 490-491 CD denotes 1
T15989 485-489 NN denotes lane
T15988 484-485 -LRB- denotes (
T15987 475-483 NN denotes controls
T15986 472-474 IN denotes of
T15985 467-471 DT denotes that
T15984 462-466 IN denotes with
T15983 451-461 NN denotes comparison
T15982 448-450 IN denotes in
T15981 438-447 NN denotes promoters
T15980 432-437 NN denotes IL-17
T15979 429-431 TO denotes to
T15978 423-428 NN denotes NF-κB
T15977 420-422 IN denotes of
T15976 412-419 NN denotes binding
T15975 402-411 VB denotes increased
T15974 389-401 VB denotes demonstrated
T15973 387-388 -RRB- denotes )
T15972 386-387 CD denotes 2
T15971 381-385 NN denotes lane
T15970 380-381 -LRB- denotes (
T15969 370-379 NN denotes anti-CD28
T15968 365-369 CC denotes plus
T15967 356-364 JJ denotes anti-CD3
T15966 351-355 IN denotes with
T15965 340-350 VB denotes stimulated
T15964 335-339 NN denotes PBMC
T15963 332-334 NN denotes RA
T15962 327-331 IN denotes from
T15961 318-326 NN denotes extracts
T15960 310-317 JJ denotes nuclear
T15959 308-309 -COMMA- denotes ,
T15958 306-308 NNP denotes 7a
T15957 301-305 NNP denotes Fig.
T15956 298-300 IN denotes in
T15955 292-297 VB denotes shown
T15954 289-291 IN denotes As
T15953 282-287 NN denotes IL-17
T15952 279-281 IN denotes of
T15951 269-278 NN denotes promoters
T15950 265-268 DT denotes the
T15949 262-264 IN denotes in
T15948 256-261 NN denotes sites
T15947 244-255 NN denotes recognition
T15946 238-243 NN denotes NF-κB
T15945 235-237 IN denotes of
T15944 233-234 -RRB- denotes )
T15943 229-233 NN denotes EMSA
T15942 228-229 -LRB- denotes (
T15941 222-227 NN denotes assay
T15940 207-221 NN denotes mobility-shift
T15939 191-206 JJ denotes electrophoretic
T15938 188-190 DT denotes an
T15937 178-187 VB denotes performed
T15936 175-177 PRP denotes we
T15935 173-174 -COMMA- denotes ,
T15934 163-173 NN denotes expression
T15933 157-162 NN denotes IL-17
T15932 148-156 VB denotes inducing
T15931 144-147 IN denotes for
T15930 132-143 JJ denotes responsible
T15929 128-131 CC denotes and
T15928 126-127 -COMMA- denotes ,
T15927 121-126 NN denotes IL-15
T15926 117-120 CC denotes and
T15925 113-116 NN denotes PHA
T15924 111-112 -COMMA- denotes ,
T15923 110-111 NN denotes A
T15922 97-109 NN denotes concanavalin
T15921 95-96 -COMMA- denotes ,
T15920 86-95 NN denotes anti-CD28
T15919 81-85 CC denotes plus
T15918 72-80 JJ denotes anti-CD3
T15917 69-71 IN denotes by
T15916 59-68 VB denotes activated
T15915 51-58 NN denotes pathway
T15914 41-50 NN denotes signaling
T15913 27-40 JJ denotes intracellular
T15912 23-26 DT denotes the
T15911 15-22 RB denotes further
T15910 3-14 VB denotes investigate
T15909 0-2 TO denotes To
T16086 985-992 NN denotes Western
T16085 982-983 -RRB- denotes )
T16147 1339-1341 NN denotes RA
T16146 1334-1338 IN denotes with
T16145 1325-1333 NN denotes patients
T16144 1320-1324 IN denotes from
T16143 1315-1319 NN denotes PBMC
T16142 1305-1314 VB denotes activated
T16141 1302-1304 IN denotes by
T16140 1291-1301 NN denotes production
T16139 1285-1290 NN denotes IL-17
T16138 1282-1284 IN denotes in
T16137 1274-1281 NN denotes pathway
T16136 1264-1273 NN denotes signaling
T16135 1250-1263 JJ denotes intracellular
T16134 1245-1249 JJ denotes main
T16133 1241-1244 DT denotes the
T16132 1238-1240 VB denotes is
T16131 1232-1237 NN denotes NF-κB
T16130 1227-1231 IN denotes that
T16129 1213-1226 VB denotes demonstrating
T16128 1211-1212 -COMMA- denotes ,
T16127 1210-1211 -RRB- denotes )
T16126 1205-1210 VB denotes shown
T16125 1201-1204 RB denotes not
T16124 1196-1200 NN denotes data
T16123 1195-1196 -LRB- denotes (
T16122 1185-1194 JJ denotes anti-CD28
T16121 1180-1184 CC denotes plus
T16120 1171-1179 JJ denotes anti-CD3
T16119 1166-1170 IN denotes with
T16118 1154-1165 NN denotes stimulation
T16117 1151-1153 IN denotes by
T16116 1141-1150 VB denotes activated
T16115 1137-1140 RB denotes not
T16114 1133-1136 VB denotes was
T16113 1125-1132 NN denotes pathway
T16112 1120-1124 NN denotes AP-1
T16111 1116-1119 DT denotes the
T16110 1114-1115 -COMMA- denotes ,
T16109 1106-1114 NN denotes contrast
T16108 1103-1105 IN denotes In
T16107 1100-1101 -RRB- denotes )
T16106 1098-1100 NN denotes 7c
T16105 1093-1097 NN denotes Fig.
T16104 1092-1093 -LRB- denotes (
T16103 1087-1091 NN denotes time
T16102 1082-1086 JJ denotes same
T16101 1078-1081 DT denotes the
T16100 1075-1077 IN denotes at
T16099 1070-1074 NN denotes PDTC
T16098 1066-1069 CC denotes and
T16097 1057-1065 NN denotes LY294002
T16096 1054-1056 IN denotes by
T16095 1048-1053 NN denotes IκB-α
T16094 1045-1047 IN denotes of
T16093 1033-1044 NN denotes degradation
T16092 1030-1032 IN denotes of
T16091 1019-1029 NN denotes inhibition
T16090 1012-1018 VB denotes showed
T16089 1006-1011 NN denotes IκB-α
T16088 1002-1005 IN denotes for
T16087 993-1001 NN denotes blotting
T16084 980-982 NN denotes 7c
T16083 975-979 NN denotes Fig.
T16082 974-975 -LRB- denotes (
T16081 965-973 NN denotes promoter
T16080 959-964 NN denotes IL-17
T16079 955-958 DT denotes the
T16078 952-954 IN denotes in
T16077 943-951 NN denotes activity
T16076 931-942 JJ denotes DNA-binding
T16075 925-930 NN denotes NF-κB
T16074 919-924 VB denotes block
T16073 912-918 NN denotes agents
T16072 907-911 DT denotes Both
T16071 901-905 NN denotes PDTC
T16070 897-900 CC denotes and
T16069 888-896 NN denotes LY294002
T16068 883-887 CC denotes both
T16067 878-882 IN denotes with
T16066 868-877 NN denotes treatment
T16065 862-867 IN denotes after
T16064 853-861 NN denotes activity
T16063 845-852 NN denotes binding
T16062 839-844 NN denotes NF-κB
T16061 835-838 DT denotes the
T16060 825-834 VB denotes determine
T16059 822-824 TO denotes to
T16058 817-821 NN denotes EMSA
T16057 807-816 VB denotes performed
T16056 804-806 PRP denotes we
T16055 802-803 -COMMA- denotes ,
T16054 797-802 NN denotes NF-κB
T16053 793-796 CC denotes and
T16052 784-792 NN denotes activity
T16051 779-783 NN denotes PI3K
T16050 771-778 IN denotes between
T16049 766-770 NN denotes link
T16048 762-765 DT denotes the
T16047 754-761 VB denotes confirm
T16046 751-753 TO denotes To
T16045 748-749 -RRB- denotes )
T16044 746-748 NN denotes 7b
T16043 741-745 NN denotes Fig.
T16042 740-741 -LRB- denotes (
T16041 735-739 NN denotes PBMC
T16040 732-734 NN denotes RA
T16039 729-731 IN denotes in
T16038 724-728 DT denotes that
T16037 719-723 IN denotes than
T16036 711-718 JJ denotes intense
T16035 706-710 RB denotes less
T16034 702-705 VB denotes was
T16033 692-701 NN denotes anti-CD28
T16032 687-691 CC denotes plus
T16031 678-686 NN denotes anti-CD3
T16030 675-677 IN denotes by
T16029 664-674 NN denotes activation
T16028 658-663 NN denotes NF-κB
T16027 655-657 IN denotes of
R8599 T15910 T15909 arg1Of investigate,To
R8600 T15910 T15911 arg1Of investigate,further
R8601 T15915 T15910 arg2Of pathway,investigate
R8602 T15915 T15912 arg1Of pathway,the
R8603 T15915 T15913 arg1Of pathway,intracellular
R8604 T15915 T15914 arg1Of pathway,signaling
R8605 T15915 T15916 arg2Of pathway,activated
R8606 T15915 T15930 arg1Of pathway,responsible
R8607 T15916 T15929 arg1Of activated,and
R8608 T15918 T15919 arg1Of anti-CD3,plus
R8609 T15919 T15921 arg1Of plus,","
R8610 T15920 T15919 arg2Of anti-CD28,plus
R8611 T15921 T15924 arg1Of ",",","
R8612 T15923 T15921 arg2Of A,","
R8613 T15923 T15922 arg1Of A,concanavalin
R8614 T15924 T15926 arg1Of ",",and
R8615 T15925 T15924 arg2Of PHA,","
R8616 T15926 T15916 arg1Of and,activated
R8617 T15926 T15917 arg2Of and,by
R8618 T15927 T15926 arg2Of IL-15,and
R8619 T15929 T15928 arg1Of and,","
R8620 T15930 T15929 arg2Of responsible,and
R8621 T15930 T15931 arg1Of responsible,for
R8622 T15932 T15931 arg2Of inducing,for
R8623 T15934 T15932 arg2Of expression,inducing
R8624 T15934 T15933 arg1Of expression,IL-17
R8625 T15936 T15937 arg1Of we,performed
R8626 T15937 T15909 modOf performed,To
R8627 T15937 T15935 arg1Of performed,","
R8628 T15941 T15937 arg2Of assay,performed
R8629 T15941 T15938 arg1Of assay,an
R8630 T15941 T15939 arg1Of assay,electrophoretic
R8631 T15941 T15940 arg1Of assay,mobility-shift
R8632 T15941 T15942 arg1Of assay,(
R8633 T15941 T15945 arg1Of assay,of
R8634 T15943 T15942 arg2Of EMSA,(
R8635 T15944 T15942 arg3Of ),(
R8636 T15948 T15945 arg2Of sites,of
R8637 T15948 T15946 arg1Of sites,NF-κB
R8638 T15948 T15947 arg1Of sites,recognition
R8639 T15948 T15949 arg1Of sites,in
R8640 T15951 T15949 arg2Of promoters,in
R8641 T15951 T15950 arg1Of promoters,the
R8642 T15951 T15952 arg1Of promoters,of
R8643 T15953 T15952 arg2Of IL-17,of
R8644 T15955 T15954 arg2Of shown,As
R8645 T15955 T15956 arg1Of shown,in
R8646 T15958 T15956 arg2Of 7a,in
R8647 T15958 T15957 arg1Of 7a,Fig.
R8648 T15961 T15960 arg1Of extracts,nuclear
R8649 T15961 T15962 arg1Of extracts,from
R8650 T15961 T15974 arg1Of extracts,demonstrated
R8651 T15964 T15962 arg2Of PBMC,from
R8652 T15964 T15963 arg1Of PBMC,RA
R8653 T15964 T15965 arg2Of PBMC,stimulated
R8654 T15965 T15966 arg1Of stimulated,with
R8655 T15967 T15968 arg1Of anti-CD3,plus
R8656 T15968 T15966 arg2Of plus,with
R8657 T15968 T15970 arg1Of plus,(
R8658 T15969 T15968 arg2Of anti-CD28,plus
R8659 T15971 T15970 arg2Of lane,(
R8660 T15971 T15972 arg1Of lane,2
R8661 T15973 T15970 arg3Of ),(
R8662 T15974 T15954 arg1Of demonstrated,As
R8663 T15974 T15959 arg1Of demonstrated,","
R8664 T15974 T15982 arg1Of demonstrated,in
R8665 T15976 T15974 arg2Of binding,demonstrated
R8666 T15976 T15975 arg2Of binding,increased
R8667 T15976 T15977 arg1Of binding,of
R8668 T15976 T15979 arg1Of binding,to
R8669 T15978 T15977 arg2Of NF-κB,of
R8670 T15981 T15979 arg2Of promoters,to
R8671 T15981 T15980 arg1Of promoters,IL-17
R8672 T15983 T15982 arg2Of comparison,in
R8673 T15983 T15984 arg1Of comparison,with
R8674 T15985 T15984 arg2Of that,with
R8675 T15985 T15986 arg1Of that,of
R8676 T15987 T15986 arg2Of controls,of
R8677 T15987 T15988 arg1Of controls,(
R8678 T15989 T15988 arg2Of lane,(
R8679 T15989 T15990 arg1Of lane,1
R8680 T15991 T15988 arg3Of ),(
R8681 T15994 T15992 arg1Of assay,A
R8682 T15994 T15993 arg1Of assay,supershift
R8683 T15994 T15995 arg1Of assay,demonstrated
R8684 T15995 T16009 arg1Of demonstrated,in
R8685 T15997 T15995 arg2Of bands,demonstrated
R8686 T15997 T15996 arg2Of bands,shifted
R8687 T15997 T15998 arg1Of bands,in
R8688 T15999 T16000 arg1Of p65,and
R8689 T16000 T15998 arg2Of and,in
R8690 T16000 T16002 arg1Of and,(
R8691 T16001 T16000 arg2Of p50,and
R8692 T16004 T16005 arg1Of 3,and
R8693 T16005 T16002 arg2Of and,(
R8694 T16005 T16003 arg1Of and,lanes
R8695 T16006 T16005 arg2Of 4,and
R8696 T16007 T16002 arg3Of ),(
R8697 T16009 T16008 arg1Of in,not
R8698 T16010 T16009 arg2Of c-Rel,in
R8699 T16010 T16011 arg1Of c-Rel,(
R8700 T16012 T16011 arg2Of lane,(
R8701 T16012 T16013 arg1Of lane,5
R8702 T16014 T16011 arg3Of ),(
R8703 T16017 T16015 arg2Of PBMC,In
R8704 T16017 T16016 arg1Of PBMC,normal
R8705 T16020 T16018 arg1Of pattern,the
R8706 T16020 T16019 arg1Of pattern,same
R8707 T16020 T16021 arg1Of pattern,was
R8708 T16020 T16022 arg2Of pattern,observed
R8709 T16022 T16015 arg1Of observed,In
R8710 T16022 T16021 arg2Of observed,was
R8711 T16022 T16024 arg1Of observed,but
R8712 T16024 T16023 arg1Of but,","
R8713 T16026 T16025 arg1Of degree,the
R8714 T16026 T16027 arg1Of degree,of
R8715 T16026 T16030 arg1Of degree,by
R8716 T16026 T16034 arg1Of degree,was
R8717 T16026 T16036 arg1Of degree,intense
R8718 T16029 T16027 arg2Of activation,of
R8719 T16029 T16028 arg1Of activation,NF-κB
R8720 T16031 T16032 arg1Of anti-CD3,plus
R8721 T16032 T16030 arg2Of plus,by
R8722 T16033 T16032 arg2Of anti-CD28,plus
R8723 T16034 T16024 arg2Of was,but
R8724 T16036 T16034 arg2Of intense,was
R8725 T16036 T16035 arg1Of intense,less
R8726 T16036 T16037 arg1Of intense,than
R8727 T16038 T16037 arg2Of that,than
R8728 T16038 T16039 arg1Of that,in
R8729 T16041 T16039 arg2Of PBMC,in
R8730 T16041 T16040 arg1Of PBMC,RA
R8731 T16041 T16042 arg1Of PBMC,(
R8732 T16044 T16042 arg2Of 7b,(
R8733 T16044 T16043 arg1Of 7b,Fig.
R8734 T16045 T16042 arg3Of ),(
R8735 T16047 T16046 arg1Of confirm,To
R8736 T16049 T16047 arg2Of link,confirm
R8737 T16049 T16048 arg1Of link,the
R8738 T16049 T16050 arg1Of link,between
R8739 T16052 T16051 arg1Of activity,PI3K
R8740 T16052 T16053 arg1Of activity,and
R8741 T16053 T16050 arg2Of and,between
R8742 T16054 T16053 arg2Of NF-κB,and
R8743 T16056 T16047 arg1Of we,confirm
R8744 T16056 T16057 arg1Of we,performed
R8745 T16057 T16046 modOf performed,To
R8746 T16057 T16055 arg1Of performed,","
R8747 T16058 T16057 arg2Of EMSA,performed
R8748 T16058 T16059 modOf EMSA,to
R8749 T16060 T16059 arg1Of determine,to
R8750 T16060 T16065 arg1Of determine,after
R8751 T16064 T16060 arg2Of activity,determine
R8752 T16064 T16061 arg1Of activity,the
R8753 T16064 T16062 arg1Of activity,NF-κB
R8754 T16064 T16063 arg1Of activity,binding
R8755 T16066 T16065 arg2Of treatment,after
R8756 T16066 T16067 arg1Of treatment,with
R8757 T16069 T16070 arg1Of LY294002,and
R8758 T16070 T16067 arg2Of and,with
R8759 T16070 T16068 arg1Of and,both
R8760 T16071 T16070 arg2Of PDTC,and
R8761 T16073 T16072 arg1Of agents,Both
R8762 T16073 T16074 arg1Of agents,block
R8763 T16077 T16074 arg2Of activity,block
R8764 T16077 T16075 arg1Of activity,NF-κB
R8765 T16077 T16076 arg1Of activity,DNA-binding
R8766 T16077 T16078 arg1Of activity,in
R8767 T16081 T16078 arg2Of promoter,in
R8768 T16081 T16079 arg1Of promoter,the
R8769 T16081 T16080 arg1Of promoter,IL-17
R8770 T16081 T16082 arg1Of promoter,(
R8771 T16084 T16082 arg2Of 7c,(
R8772 T16084 T16083 arg1Of 7c,Fig.
R8773 T16085 T16082 arg3Of ),(
R8774 T16087 T16086 arg1Of blotting,Western
R8775 T16087 T16088 arg1Of blotting,for
R8776 T16087 T16090 arg1Of blotting,showed
R8777 T16089 T16088 arg2Of IκB-α,for
R8778 T16091 T16090 arg2Of inhibition,showed
R8779 T16091 T16092 arg1Of inhibition,of
R8780 T16093 T16092 arg2Of degradation,of
R8781 T16093 T16094 arg1Of degradation,of
R8782 T16093 T16096 arg1Of degradation,by
R8783 T16093 T16100 arg1Of degradation,at
R8784 T16095 T16094 arg2Of IκB-α,of
R8785 T16097 T16098 arg1Of LY294002,and
R8786 T16098 T16096 arg2Of and,by
R8787 T16099 T16098 arg2Of PDTC,and
R8788 T16103 T16100 arg2Of time,at
R8789 T16103 T16101 arg1Of time,the
R8790 T16103 T16102 arg1Of time,same
R8791 T16103 T16104 arg1Of time,(
R8792 T16106 T16104 arg2Of 7c,(
R8793 T16106 T16105 arg1Of 7c,Fig.
R8794 T16107 T16104 arg3Of ),(
R8795 T16109 T16108 arg2Of contrast,In
R8796 T16113 T16111 arg1Of pathway,the
R8797 T16113 T16112 arg1Of pathway,AP-1
R8798 T16113 T16114 arg1Of pathway,was
R8799 T16113 T16116 arg2Of pathway,activated
R8800 T16116 T16108 arg1Of activated,In
R8801 T16116 T16110 arg1Of activated,","
R8802 T16116 T16114 arg2Of activated,was
R8803 T16116 T16115 arg1Of activated,not
R8804 T16116 T16128 arg1Of activated,","
R8805 T16116 T16129 modOf activated,demonstrating
R8806 T16118 T16116 arg1Of stimulation,activated
R8807 T16118 T16117 arg2Of stimulation,by
R8808 T16118 T16119 arg1Of stimulation,with
R8809 T16120 T16121 arg1Of anti-CD3,plus
R8810 T16122 T16121 arg2Of anti-CD28,plus
R8811 T16124 T16119 arg2Of data,with
R8812 T16124 T16120 arg1Of data,anti-CD3
R8813 T16124 T16122 arg1Of data,anti-CD28
R8814 T16124 T16123 arg2Of data,(
R8815 T16124 T16126 arg2Of data,shown
R8816 T16126 T16125 arg1Of shown,not
R8817 T16127 T16123 arg3Of ),(
R8818 T16131 T16132 arg1Of NF-κB,is
R8819 T16132 T16129 arg2Of is,demonstrating
R8820 T16132 T16130 arg1Of is,that
R8821 T16137 T16132 arg2Of pathway,is
R8822 T16137 T16133 arg1Of pathway,the
R8823 T16137 T16134 arg1Of pathway,main
R8824 T16137 T16135 arg1Of pathway,intracellular
R8825 T16137 T16136 arg1Of pathway,signaling
R8826 T16137 T16138 arg1Of pathway,in
R8827 T16137 T16141 arg1Of pathway,by
R8828 T16140 T16138 arg2Of production,in
R8829 T16140 T16139 arg1Of production,IL-17
R8830 T16143 T16141 arg2Of PBMC,by
R8831 T16143 T16142 arg2Of PBMC,activated
R8832 T16143 T16144 arg1Of PBMC,from
R8833 T16145 T16144 arg2Of patients,from
R8834 T16145 T16146 arg1Of patients,with
R8835 T16147 T16146 arg2Of RA,with

bionlp-st-ge-2016-test-proteins

Id Subject Object Predicate Lexical cue
T16167 1285-1290 Protein denotes IL-17
T16166 1190-1194 Protein denotes CD28
T16165 1120-1124 Protein denotes AP-1
T16164 1048-1053 Protein denotes IκB-α
T16163 1006-1011 Protein denotes IκB-α
T16162 959-964 Protein denotes IL-17
T16161 697-701 Protein denotes CD28
T16160 578-583 Protein denotes c-Rel
T16159 551-554 Protein denotes p50
T16158 543-546 Protein denotes p65
T16157 432-437 Protein denotes IL-17
T16156 375-379 Protein denotes CD28
T16155 282-287 Protein denotes IL-17
T16154 157-162 Protein denotes IL-17
T16153 121-126 Protein denotes IL-15
T16152 113-116 Protein denotes PHA
T16151 91-95 Protein denotes CD28

bionlp-st-ge-2016-uniprot

Id Subject Object Predicate Lexical cue
T16313 578-583 http://www.uniprot.org/uniprot/Q04864 denotes c-Rel
T16312 551-554 http://www.uniprot.org/uniprot/P19838 denotes p50
T16311 543-546 http://www.uniprot.org/uniprot/P21579 denotes p65
T16310 543-546 http://www.uniprot.org/uniprot/Q04206 denotes p65
T16309 121-126 http://www.uniprot.org/uniprot/P40933 denotes IL-15
T16308 1190-1194 http://www.uniprot.org/uniprot/P10747 denotes CD28
T16307 697-701 http://www.uniprot.org/uniprot/P10747 denotes CD28
T16306 375-379 http://www.uniprot.org/uniprot/P10747 denotes CD28
T16305 91-95 http://www.uniprot.org/uniprot/P10747 denotes CD28
T16304 1176-1179 http://www.uniprot.org/uniprot/P09693 denotes CD3
T16303 683-686 http://www.uniprot.org/uniprot/P09693 denotes CD3
T16302 361-364 http://www.uniprot.org/uniprot/P09693 denotes CD3
T16301 77-80 http://www.uniprot.org/uniprot/P09693 denotes CD3
T16300 1176-1179 http://www.uniprot.org/uniprot/P07766 denotes CD3
T16299 683-686 http://www.uniprot.org/uniprot/P07766 denotes CD3
T16298 361-364 http://www.uniprot.org/uniprot/P07766 denotes CD3
T16297 77-80 http://www.uniprot.org/uniprot/P07766 denotes CD3
T16296 1176-1179 http://www.uniprot.org/uniprot/P04234 denotes CD3
T16295 683-686 http://www.uniprot.org/uniprot/P04234 denotes CD3
T16294 361-364 http://www.uniprot.org/uniprot/P04234 denotes CD3
T16293 77-80 http://www.uniprot.org/uniprot/P04234 denotes CD3
T16292 1176-1179 http://www.uniprot.org/uniprot/P20963 denotes CD3
T16291 683-686 http://www.uniprot.org/uniprot/P20963 denotes CD3
T16290 361-364 http://www.uniprot.org/uniprot/P20963 denotes CD3
T16289 77-80 http://www.uniprot.org/uniprot/P20963 denotes CD3
T16288 1285-1290 http://www.uniprot.org/uniprot/Q16552 denotes IL-17
T16287 959-964 http://www.uniprot.org/uniprot/Q16552 denotes IL-17
T16286 432-437 http://www.uniprot.org/uniprot/Q16552 denotes IL-17
T16285 282-287 http://www.uniprot.org/uniprot/Q16552 denotes IL-17
T16284 157-162 http://www.uniprot.org/uniprot/Q16552 denotes IL-17
T16282 1120-1124 http://www.uniprot.org/uniprot/P05412 denotes AP-1

GO-BP

Id Subject Object Predicate Lexical cue
T15854 1288-1314 http://purl.obolibrary.org/obo/GO_0032740 denotes 17 production by activated
T15853 1285-1301 http://purl.obolibrary.org/obo/GO_0032620 denotes IL-17 production
T15852 1285-1301 http://purl.obolibrary.org/obo/GO_0032660 denotes IL-17 production
T15851 1033-1044 http://purl.obolibrary.org/obo/GO_0009056 denotes degradation
T15850 779-783 http://purl.obolibrary.org/obo/GO_0016303 denotes PI3K
T15849 658-674 http://purl.obolibrary.org/obo/GO_0051092 denotes NF-κB activation
T15848 41-68 http://purl.obolibrary.org/obo/GO_1903265 denotes signaling pathway activated
T15847 41-68 http://purl.obolibrary.org/obo/GO_1902843 denotes signaling pathway activated
T15846 41-68 http://purl.obolibrary.org/obo/GO_1902046 denotes signaling pathway activated
T15845 41-68 http://purl.obolibrary.org/obo/GO_1900236 denotes signaling pathway activated
T15844 41-68 http://purl.obolibrary.org/obo/GO_0038084 denotes signaling pathway activated
T15843 41-68 http://purl.obolibrary.org/obo/GO_0009873 denotes signaling pathway activated
T15842 41-68 http://purl.obolibrary.org/obo/GO_1902204 denotes signaling pathway activated
T15841 41-68 http://purl.obolibrary.org/obo/GO_1901186 denotes signaling pathway activated
T15840 41-68 http://purl.obolibrary.org/obo/GO_0033211 denotes signaling pathway activated
T15839 41-68 http://purl.obolibrary.org/obo/GO_0009736 denotes signaling pathway activated
T15838 1264-1281 http://purl.obolibrary.org/obo/GO_0007165 denotes signaling pathway
T15837 41-58 http://purl.obolibrary.org/obo/GO_0007165 denotes signaling pathway
T15836 1264-1273 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T15835 41-50 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T15834 27-68 http://purl.obolibrary.org/obo/GO_1902533 denotes intracellular signaling pathway activated
T15833 1250-1281 http://purl.obolibrary.org/obo/GO_1902531 denotes intracellular signaling pathway
T15832 27-58 http://purl.obolibrary.org/obo/GO_1902531 denotes intracellular signaling pathway
T15831 1250-1281 http://purl.obolibrary.org/obo/GO_1902532 denotes intracellular signaling pathway
T15830 27-58 http://purl.obolibrary.org/obo/GO_1902532 denotes intracellular signaling pathway
T15829 1250-1281 http://purl.obolibrary.org/obo/GO_0035556 denotes intracellular signaling pathway
T15828 27-58 http://purl.obolibrary.org/obo/GO_0035556 denotes intracellular signaling pathway
T15827 1250-1281 http://purl.obolibrary.org/obo/GO_0030522 denotes intracellular signaling pathway
T15826 27-58 http://purl.obolibrary.org/obo/GO_0030522 denotes intracellular signaling pathway

GO-MF

Id Subject Object Predicate Lexical cue
T16181 931-942 http://purl.obolibrary.org/obo/GO_0003677 denotes DNA-binding
T16180 779-783 http://purl.obolibrary.org/obo/GO_0016303 denotes PI3K
T16179 839-852 http://purl.obolibrary.org/obo/GO_0051059 denotes NF-κB binding
T16178 412-428 http://purl.obolibrary.org/obo/GO_0051059 denotes binding of NF-κB
T16177 935-942 http://purl.obolibrary.org/obo/GO_0005488 denotes binding
T16176 845-852 http://purl.obolibrary.org/obo/GO_0005488 denotes binding
T16175 412-419 http://purl.obolibrary.org/obo/GO_0005488 denotes binding
T16174 121-126 http://purl.obolibrary.org/obo/GO_0016170 denotes IL-15
T16173 1285-1290 http://purl.obolibrary.org/obo/GO_0030367 denotes IL-17
T16172 959-964 http://purl.obolibrary.org/obo/GO_0030367 denotes IL-17
T16171 432-437 http://purl.obolibrary.org/obo/GO_0030367 denotes IL-17
T16170 282-287 http://purl.obolibrary.org/obo/GO_0030367 denotes IL-17
T16169 157-162 http://purl.obolibrary.org/obo/GO_0030367 denotes IL-17

GO-CC

Id Subject Object Predicate Lexical cue
T16183 1250-1263 http://purl.obolibrary.org/obo/GO_0005622 denotes intracellular
T16182 27-40 http://purl.obolibrary.org/obo/GO_0005622 denotes intracellular

sentences

Id Subject Object Predicate Lexical cue
T15825 1103-1342 Sentence denotes In contrast, the AP-1 pathway was not activated by stimulation with anti-CD3 plus anti-CD28 (data not shown), demonstrating that NF-κB is the main intracellular signaling pathway in IL-17 production by activated PBMC from patients with RA.
T15824 985-1102 Sentence denotes Western blotting for IκB-α showed inhibition of degradation of IκB-α by LY294002 and PDTC at the same time (Fig. 7c).
T15823 907-984 Sentence denotes Both agents block NF-κB DNA-binding activity in the IL-17 promoter (Fig. 7c).
T15822 751-906 Sentence denotes To confirm the link between PI3K activity and NF-κB, we performed EMSA to determine the NF-κB binding activity after treatment with both LY294002 and PDTC.
T15821 594-750 Sentence denotes In normal PBMC the same pattern was observed, but the degree of NF-κB activation by anti-CD3 plus anti-CD28 was less intense than that in RA PBMC (Fig. 7b).
T15820 494-593 Sentence denotes A supershift assay demonstrated shifted bands in p65 and p50 (lanes 3 and 4) not in c-Rel (lane 5).
T15819 289-493 Sentence denotes As shown in Fig. 7a, nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters in comparison with that of controls (lane 1).
T15818 0-288 Sentence denotes To investigate further the intracellular signaling pathway activated by anti-CD3 plus anti-CD28, concanavalin A, PHA and IL-15, and responsible for inducing IL-17 expression, we performed an electrophoretic mobility-shift assay (EMSA) of NF-κB recognition sites in the promoters of IL-17.
T148 0-288 Sentence denotes To investigate further the intracellular signaling pathway activated by anti-CD3 plus anti-CD28, concanavalin A, PHA and IL-15, and responsible for inducing IL-17 expression, we performed an electrophoretic mobility-shift assay (EMSA) of NF-κB recognition sites in the promoters of IL-17.
T149 289-493 Sentence denotes As shown in Fig. 7a, nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters in comparison with that of controls (lane 1).
T150 494-593 Sentence denotes A supershift assay demonstrated shifted bands in p65 and p50 (lanes 3 and 4) not in c-Rel (lane 5).
T151 594-750 Sentence denotes In normal PBMC the same pattern was observed, but the degree of NF-κB activation by anti-CD3 plus anti-CD28 was less intense than that in RA PBMC (Fig. 7b).
T152 751-906 Sentence denotes To confirm the link between PI3K activity and NF-κB, we performed EMSA to determine the NF-κB binding activity after treatment with both LY294002 and PDTC.
T153 907-984 Sentence denotes Both agents block NF-κB DNA-binding activity in the IL-17 promoter (Fig. 7c).
T154 985-1102 Sentence denotes Western blotting for IκB-α showed inhibition of degradation of IκB-α by LY294002 and PDTC at the same time (Fig. 7c).
T155 1103-1342 Sentence denotes In contrast, the AP-1 pathway was not activated by stimulation with anti-CD3 plus anti-CD28 (data not shown), demonstrating that NF-κB is the main intracellular signaling pathway in IL-17 production by activated PBMC from patients with RA.

simple1

Id Subject Object Predicate Lexical cue
T16280 1285-1290 Protein denotes IL-17
T16279 1190-1194 Protein denotes CD28
T16278 1120-1124 Protein denotes AP-1
T16277 1048-1053 Protein denotes IκB-α
T16276 1006-1011 Protein denotes IκB-α
T16275 959-964 Protein denotes IL-17
T16274 697-701 Protein denotes CD28
T16273 578-583 Protein denotes c-Rel
T16272 551-554 Protein denotes p50
T16271 543-546 Protein denotes p65
T16270 432-437 Protein denotes IL-17
T16269 375-379 Protein denotes CD28
T16268 282-287 Protein denotes IL-17
T16267 157-162 Protein denotes IL-17
T16266 121-126 Protein denotes IL-15
T16265 113-116 Protein denotes PHA
T16264 91-95 Protein denotes CD28

DLUT931

Id Subject Object Predicate Lexical cue
T16373 1305-1314 Positive_regulation denotes activated
T16372 1291-1301 Gene_expression denotes production
T16371 1141-1150 Positive_regulation denotes activated
T16370 1019-1029 Negative_regulation denotes inhibition
T16369 1033-1044 Protein_catabolism denotes degradation
T16368 931-942 Binding denotes DNA-binding
T16367 402-411 Positive_regulation denotes increased
T16366 412-419 Binding denotes binding
T16365 148-156 Positive_regulation denotes inducing
T16364 163-173 Gene_expression denotes expression
T16362 1285-1290 Protein denotes IL-17
T16361 1190-1194 Protein denotes CD28
T16360 1120-1124 Protein denotes AP-1
T16359 1048-1053 Protein denotes IκB-α
T16358 1006-1011 Protein denotes IκB-α
T16357 959-964 Protein denotes IL-17
T16356 697-701 Protein denotes CD28
T16355 578-583 Protein denotes c-Rel
T16354 551-554 Protein denotes p50
T16353 543-546 Protein denotes p65
T16352 375-379 Protein denotes CD28
T16351 432-437 Protein denotes IL-17
T16350 282-287 Protein denotes IL-17
T16349 157-162 Protein denotes IL-17
T16348 121-126 Protein denotes IL-15
T16347 113-116 Protein denotes PHA
T16346 91-95 Protein denotes CD28
R8872 T16349 T16364 themeOf IL-17,expression
R8873 T16351 T16366 themeOf IL-17,binding
R8874 T16357 T16368 themeOf IL-17,DNA-binding
R8875 T16359 T16369 themeOf IκB-α,degradation
R8876 T16360 T16371 themeOf AP-1,activated
R8877 T16362 T16372 themeOf IL-17,production
R8878 T16364 T16365 themeOf expression,inducing
R8879 T16366 T16367 themeOf binding,increased
R8880 T16369 T16370 themeOf degradation,inhibition
R8881 T16372 T16373 themeOf production,activated

bionlp-st-ge-2016-test-ihmc

Id Subject Object Predicate Lexical cue
T16780 658-701 Positive_regulation denotes NF-κB activation by anti-CD3 plus anti-CD28
T16779 658-701 Positive_regulation denotes NF-κB activation by anti-CD3 plus anti-CD28
T16778 1285-1341 Gene_expression denotes IL-17 production by activated PBMC from patients with RA
T16777 1030-1053 Protein_catabolism denotes of degradation of IκB-α
T16774 1012-1065 Negative_regulation denotes showed inhibition of degradation of IκB-α by LY294002
T16773 157-174 Gene_expression denotes IL-17 expression,
T16772 402-447 Positive_regulation denotes increased binding of NF-κB to IL-17 promoters
T16771 310-447 Binding denotes nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters
T16770 432-437 Protein denotes IL-17
T16769 959-964 Protein denotes IL-17
T16768 238-243 Protein denotes NF-κB
T16767 955-983 Entity denotes the IL-17 promoter (Fig. 7c)
T16766 121-126 Protein denotes IL-15
T16765 238-261 Entity denotes NF-κB recognition sites
T16764 157-162 Protein denotes IL-17
T16736 1227-1237 Protein denotes that NF-κB
T16735 332-334 Protein denotes RA
T16734 578-592 Protein denotes c-Rel (lane 5)
T16733 97-111 Protein denotes concanavalin A
T16732 23-40 Entity denotes the intracellular
T16731 1116-1132 Protein denotes the AP-1 pathway
T16730 551-554 Protein denotes p50
T16729 420-428 Protein denotes of NF-κB
T16728 86-127 Protein denotes anti-CD28, concanavalin A, PHA and IL-15,
T16727 429-447 Entity denotes to IL-17 promoters
T16726 301-304 Protein denotes Fig
T16725 1006-1011 Protein denotes IκB-α
T16724 678-686 Protein denotes anti-CD3
T16723 597-608 Entity denotes normal PBMC
T16722 1171-1179 Protein denotes anti-CD3
T16721 370-388 Protein denotes anti-CD28 (lane 2)
T16720 113-116 Protein denotes PHA
T16719 925-930 Protein denotes NF-κB
T16718 888-896 Entity denotes LY294002
T16763 1250-1263 Entity denotes intracellular
T16762 72-80 Protein denotes anti-CD3
T16761 658-663 Protein denotes NF-κB
T16757 282-287 Protein denotes IL-17
T16756 1302-1319 Entity denotes by activated PBMC
T16754 543-546 Protein denotes p65
T16753 1093-1096 Protein denotes Fig
T16752 332-388 Entity denotes RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2)
T16751 265-287 Entity denotes the promoters of IL-17
T16750 1185-1194 Protein denotes anti-CD28
T16749 732-734 Protein denotes RA
T16748 356-364 Protein denotes anti-CD3
T16747 1339-1341 Protein denotes RA
T16746 310-388 Entity denotes nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2)
T16744 1285-1290 Protein denotes IL-17
T16743 732-739 Entity denotes RA PBMC
T16742 1045-1053 Protein denotes of IκB-α
T16741 797-802 Protein denotes NF-κB
T16740 741-744 Protein denotes Fig
T16739 692-701 Protein denotes anti-CD28
T16738 779-783 Protein denotes PI3K
T16737 1054-1065 Entity denotes by LY294002
R9175 T16724 T16779 causeOf anti-CD3,NF-κB activation by anti-CD3 plus anti-CD28
R9176 T16727 T16770 partOf to IL-17 promoters,IL-17
R9177 T16727 T16771 themeOf to IL-17 promoters,nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters
R9178 T16729 T16771 themeOf of NF-κB,nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters
R9179 T16737 T16774 causeOf by LY294002,showed inhibition of degradation of IκB-α by LY294002
R9180 T16739 T16780 causeOf anti-CD28,NF-κB activation by anti-CD3 plus anti-CD28
R9181 T16742 T16777 themeOf of IκB-α,of degradation of IκB-α
R9182 T16744 T16778 themeOf IL-17,IL-17 production by activated PBMC from patients with RA
R9185 T16761 T16779 themeOf NF-κB,NF-κB activation by anti-CD3 plus anti-CD28
R9186 T16761 T16780 themeOf NF-κB,NF-κB activation by anti-CD3 plus anti-CD28
R9187 T16764 T16773 themeOf IL-17,"IL-17 expression,"
R9188 T16767 T16769 partOf the IL-17 promoter (Fig. 7c),IL-17
R9189 T16771 T16772 themeOf nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters,increased binding of NF-κB to IL-17 promoters
R9190 T16777 T16774 themeOf of degradation of IκB-α,showed inhibition of degradation of IκB-α by LY294002

bionlp-st-ge-2016-spacy-parsed

Id Subject Object Predicate Lexical cue
T16660 1341-1342 . denotes .
T16659 1339-1341 NNP denotes RA
T16658 1334-1338 IN denotes with
T16657 1325-1333 NNS denotes patients
T16656 1320-1324 IN denotes from
T16655 1315-1319 NNP denotes PBMC
T16654 1305-1314 VBN denotes activated
T16653 1302-1304 IN denotes by
T16652 1291-1301 NN denotes production
T16651 1285-1290 JJ denotes IL-17
T16650 1282-1284 IN denotes in
T16649 1274-1281 NN denotes pathway
T16648 1264-1273 VBG denotes signaling
T16647 1250-1263 JJ denotes intracellular
T16646 1245-1249 JJ denotes main
T16645 1241-1244 DT denotes the
T16644 1238-1240 VBZ denotes is
T16643 1232-1237 NNP denotes NF-κB
T16620 1103-1105 IN denotes In
T16619 1101-1102 . denotes .
T16618 1100-1101 -RRB- denotes )
T16617 1098-1100 CD denotes 7c
T16616 1093-1097 NNP denotes Fig.
T16615 1092-1093 -LRB- denotes (
T16614 1087-1091 NN denotes time
T16613 1082-1086 JJ denotes same
T16612 1078-1081 DT denotes the
T16611 1075-1077 IN denotes at
T16610 1070-1074 NNP denotes PDTC
T16609 1066-1069 CC denotes and
T16608 1057-1065 NNP denotes LY294002
T16607 1054-1056 IN denotes by
T16606 1048-1053 JJ denotes IκB-α
T16605 1045-1047 IN denotes of
T16604 1033-1044 NN denotes degradation
T16603 1030-1032 IN denotes of
T16602 1019-1029 NN denotes inhibition
T16601 1012-1018 VBD denotes showed
T16600 1006-1011 JJ denotes IκB-α
T16599 1002-1005 IN denotes for
T16598 993-1001 VBG denotes blotting
T16597 985-992 JJ denotes Western
T16596 983-984 . denotes .
T16595 982-983 -RRB- denotes )
T16594 980-982 CD denotes 7c
T16593 975-979 NNP denotes Fig.
T16592 974-975 -LRB- denotes (
T16591 965-973 NN denotes promoter
T16590 959-964 NNP denotes IL-17
T16589 955-958 DT denotes the
T16588 952-954 IN denotes in
T16587 943-951 NN denotes activity
T16586 931-942 JJ denotes DNA-binding
T16585 925-930 NNP denotes NF-κB
T16584 919-924 NN denotes block
T16583 912-918 NNS denotes agents
T16582 907-911 DT denotes Both
T16581 905-906 . denotes .
T16580 901-905 NNP denotes PDTC
T16579 897-900 CC denotes and
T16578 888-896 CD denotes LY294002
T16577 883-887 DT denotes both
T16576 878-882 IN denotes with
T16575 868-877 NN denotes treatment
T16574 862-867 IN denotes after
T16573 853-861 NN denotes activity
T16572 845-852 JJ denotes binding
T16571 839-844 JJ denotes NF-κB
T16570 835-838 DT denotes the
T16569 825-834 VB denotes determine
T16568 822-824 TO denotes to
T16567 817-821 NNP denotes EMSA
T16566 807-816 VBD denotes performed
T16565 804-806 PRP denotes we
T16564 802-803 , denotes ,
T16563 797-802 NN denotes NF-κB
T16562 793-796 CC denotes and
T16561 784-792 NN denotes activity
T16560 779-783 JJ denotes PI3K
T16559 771-778 IN denotes between
T16558 766-770 NN denotes link
T16557 762-765 DT denotes the
T16556 754-761 VB denotes confirm
T16555 751-753 TO denotes To
T16554 749-750 . denotes .
T16553 748-749 -RRB- denotes )
T16552 746-748 CD denotes 7b
T16551 741-745 NNP denotes Fig.
T16550 740-741 -LRB- denotes (
T16549 735-739 NNP denotes PBMC
T16548 732-734 NNP denotes RA
T16547 729-731 IN denotes in
T16546 724-728 DT denotes that
T16545 719-723 IN denotes than
T16544 711-718 JJ denotes intense
T16543 706-710 JJR denotes less
T16542 702-705 VBD denotes was
T16541 692-701 JJ denotes anti-CD28
T16540 687-691 CC denotes plus
T16539 678-686 JJ denotes anti-CD3
T16538 675-677 IN denotes by
T16537 664-674 NN denotes activation
T16536 658-663 JJ denotes NF-κB
T16535 655-657 IN denotes of
T16534 648-654 NN denotes degree
T16533 644-647 DT denotes the
T16532 640-643 CC denotes but
T16531 638-639 , denotes ,
T16530 630-638 VBN denotes observed
T16529 626-629 VBD denotes was
T16528 618-625 NN denotes pattern
T16527 613-617 JJ denotes same
T16526 609-612 DT denotes the
T16525 604-608 NNP denotes PBMC
T16524 597-603 JJ denotes normal
T16523 594-596 IN denotes In
T16522 592-593 . denotes .
T16521 591-592 -RRB- denotes )
T16520 590-591 CD denotes 5
T16519 585-589 NN denotes lane
T16518 584-585 -LRB- denotes (
T16517 578-583 NNP denotes c-Rel
T16516 575-577 IN denotes in
T16515 571-574 RB denotes not
T16514 569-570 -RRB- denotes )
T16513 568-569 CD denotes 4
T16512 564-567 CC denotes and
T16511 562-563 CD denotes 3
T16510 556-561 NNS denotes lanes
T16509 555-556 -LRB- denotes (
T16508 551-554 CD denotes p50
T16507 547-550 CC denotes and
T16506 543-546 CD denotes p65
T16505 540-542 IN denotes in
T16504 534-539 NNS denotes bands
T16503 526-533 VBN denotes shifted
T16502 513-525 VBD denotes demonstrated
T16501 507-512 NN denotes assay
T16500 496-506 NN denotes supershift
T16499 494-495 DT denotes A
T16498 492-493 . denotes .
T16497 491-492 -RRB- denotes )
T16496 490-491 CD denotes 1
T16495 485-489 NN denotes lane
T16494 484-485 -LRB- denotes (
T16493 475-483 NNS denotes controls
T16492 472-474 IN denotes of
T16491 467-471 DT denotes that
T16490 462-466 IN denotes with
T16489 451-461 NN denotes comparison
T16488 448-450 IN denotes in
T16487 438-447 NNS denotes promoters
T16486 432-437 NNP denotes IL-17
T16485 429-431 TO denotes to
T16484 423-428 NN denotes NF-κB
T16483 420-422 IN denotes of
T16482 412-419 JJ denotes binding
T16481 402-411 VBN denotes increased
T16480 389-401 VBD denotes demonstrated
T16479 387-388 -RRB- denotes )
T16478 386-387 CD denotes 2
T16477 381-385 NN denotes lane
T16476 380-381 -LRB- denotes (
T16475 370-379 JJ denotes anti-CD28
T16474 365-369 CC denotes plus
T16473 356-364 JJ denotes anti-CD3
T16472 351-355 IN denotes with
T16471 340-350 VBD denotes stimulated
T16470 335-339 NNP denotes PBMC
T16469 332-334 NNP denotes RA
T16468 327-331 IN denotes from
T16467 318-326 NNS denotes extracts
T16466 310-317 JJ denotes nuclear
T16465 308-309 , denotes ,
T16464 306-308 CD denotes 7a
T16463 301-305 NNP denotes Fig.
T16462 298-300 IN denotes in
T16461 292-297 VBN denotes shown
T16460 289-291 IN denotes As
T16459 287-288 . denotes .
T16458 282-287 NNP denotes IL-17
T16457 279-281 IN denotes of
T16456 269-278 NNS denotes promoters
T16455 265-268 DT denotes the
T16454 262-264 IN denotes in
T16453 256-261 NNS denotes sites
T16452 244-255 NN denotes recognition
T16451 238-243 NN denotes NF-κB
T16450 235-237 IN denotes of
T16449 233-234 -RRB- denotes )
T16448 229-233 NNP denotes EMSA
T16447 228-229 -LRB- denotes (
T16446 222-227 NN denotes assay
T16445 207-221 NN denotes mobility-shift
T16444 191-206 JJ denotes electrophoretic
T16443 188-190 DT denotes an
T16442 178-187 VBD denotes performed
T16441 175-177 PRP denotes we
T16440 173-174 , denotes ,
T16439 163-173 NN denotes expression
T16438 157-162 NNP denotes IL-17
T16437 148-156 VBG denotes inducing
T16436 144-147 IN denotes for
T16435 132-143 JJ denotes responsible
T16434 128-131 CC denotes and
T16433 126-127 , denotes ,
T16432 121-126 NNP denotes IL-15
T16431 117-120 CC denotes and
T16430 113-116 NNP denotes PHA
T16429 111-112 , denotes ,
T16428 110-111 DT denotes A
T16427 97-109 JJ denotes concanavalin
T16426 95-96 , denotes ,
T16425 86-95 JJ denotes anti-CD28
T16424 81-85 CC denotes plus
T16423 72-80 JJ denotes anti-CD3
T16422 69-71 IN denotes by
T16421 59-68 VBN denotes activated
T16420 51-58 NN denotes pathway
T16419 41-50 VBG denotes signaling
T16418 27-40 JJ denotes intracellular
T16417 23-26 DT denotes the
T16416 15-22 RB denotes further
T16415 3-14 VB denotes investigate
T16414 0-2 TO denotes To
T16642 1227-1231 IN denotes that
T16641 1213-1226 VBG denotes demonstrating
T16640 1211-1212 , denotes ,
T16639 1210-1211 -RRB- denotes )
T16638 1205-1210 VBN denotes shown
T16637 1201-1204 RB denotes not
T16636 1196-1200 NNS denotes data
T16635 1195-1196 -LRB- denotes (
T16634 1185-1194 JJ denotes anti-CD28
T16633 1180-1184 CC denotes plus
T16632 1171-1179 JJ denotes anti-CD3
T16631 1166-1170 IN denotes with
T16630 1154-1165 NN denotes stimulation
T16629 1151-1153 IN denotes by
T16628 1141-1150 VBN denotes activated
T16627 1137-1140 RB denotes not
T16626 1133-1136 VBD denotes was
T16625 1125-1132 NN denotes pathway
T16624 1120-1124 NNP denotes AP-1
T16623 1116-1119 DT denotes the
T16622 1114-1115 , denotes ,
T16621 1106-1114 NN denotes contrast
R8904 T16414 T16415 aux To,investigate
R8905 T16415 T16442 advcl investigate,performed
R8906 T16416 T16415 advmod further,investigate
R8907 T16417 T16420 det the,pathway
R8908 T16418 T16420 amod intracellular,pathway
R8909 T16419 T16420 amod signaling,pathway
R8910 T16420 T16415 dobj pathway,investigate
R8911 T16421 T16420 acl activated,pathway
R8912 T16422 T16421 agent by,activated
R8913 T16423 T16430 amod anti-CD3,PHA
R8914 T16424 T16423 cc plus,anti-CD3
R8915 T16425 T16423 conj anti-CD28,anti-CD3
R8916 T16426 T16425 punct ",",anti-CD28
R8917 T16427 T16428 compound concanavalin,A
R8918 T16428 T16425 conj A,anti-CD28
R8919 T16429 T16428 punct ",",A
R8920 T16430 T16422 pobj PHA,by
R8921 T16431 T16430 cc and,PHA
R8922 T16432 T16430 conj IL-15,PHA
R8923 T16433 T16432 punct ",",IL-15
R8924 T16434 T16421 cc and,activated
R8925 T16435 T16421 conj responsible,activated
R8926 T16436 T16435 prep for,responsible
R8927 T16437 T16436 pcomp inducing,for
R8928 T16438 T16439 compound IL-17,expression
R8929 T16439 T16437 dobj expression,inducing
R8930 T16440 T16442 punct ",",performed
R8931 T16441 T16442 nsubj we,performed
R8932 T16442 T16442 ROOT performed,performed
R8933 T16443 T16446 det an,assay
R8934 T16444 T16446 amod electrophoretic,assay
R8935 T16445 T16446 compound mobility-shift,assay
R8936 T16446 T16442 dobj assay,performed
R8937 T16447 T16446 punct (,assay
R8938 T16448 T16446 appos EMSA,assay
R8939 T16449 T16446 punct ),assay
R8940 T16450 T16446 prep of,assay
R8941 T16451 T16453 compound NF-κB,sites
R8942 T16452 T16453 compound recognition,sites
R8943 T16453 T16450 pobj sites,of
R8944 T16454 T16453 prep in,sites
R8945 T16455 T16456 det the,promoters
R8946 T16456 T16454 pobj promoters,in
R8947 T16457 T16456 prep of,promoters
R8948 T16458 T16457 pobj IL-17,of
R8949 T16459 T16442 punct .,performed
R8950 T16460 T16461 mark As,shown
R8951 T16461 T16471 advcl shown,stimulated
R8952 T16462 T16461 prep in,shown
R8953 T16463 T16462 pobj Fig.,in
R8954 T16464 T16463 nummod 7a,Fig.
R8955 T16465 T16463 punct ",",Fig.
R8956 T16466 T16467 amod nuclear,extracts
R8957 T16467 T16471 nsubj extracts,stimulated
R8958 T16468 T16467 prep from,extracts
R8959 T16469 T16470 compound RA,PBMC
R8960 T16470 T16468 pobj PBMC,from
R8961 T16471 T16471 ROOT stimulated,stimulated
R8962 T16472 T16471 prep with,stimulated
R8963 T16473 T16472 pobj anti-CD3,with
R8964 T16474 T16473 cc plus,anti-CD3
R8965 T16475 T16473 conj anti-CD28,anti-CD3
R8966 T16476 T16477 punct (,lane
R8967 T16477 T16473 appos lane,anti-CD3
R8968 T16478 T16477 nummod 2,lane
R8969 T16479 T16471 punct ),stimulated
R8970 T16480 T16471 conj demonstrated,stimulated
R8971 T16481 T16482 amod increased,binding
R8972 T16482 T16480 dobj binding,demonstrated
R8973 T16483 T16482 prep of,binding
R8974 T16484 T16483 pobj NF-κB,of
R8975 T16485 T16484 prep to,NF-κB
R8976 T16486 T16487 compound IL-17,promoters
R8977 T16487 T16485 pobj promoters,to
R8978 T16488 T16480 prep in,demonstrated
R8979 T16489 T16488 pobj comparison,in
R8980 T16490 T16489 prep with,comparison
R8981 T16491 T16490 pobj that,with
R8982 T16492 T16491 prep of,that
R8983 T16493 T16492 pobj controls,of
R8984 T16494 T16495 punct (,lane
R8985 T16495 T16493 parataxis lane,controls
R8986 T16496 T16495 nummod 1,lane
R8987 T16497 T16495 punct ),lane
R8988 T16498 T16471 punct .,stimulated
R8989 T16499 T16501 det A,assay
R8990 T16500 T16501 compound supershift,assay
R8991 T16501 T16502 nsubj assay,demonstrated
R8992 T16502 T16502 ROOT demonstrated,demonstrated
R8993 T16503 T16504 amod shifted,bands
R8994 T16504 T16502 dobj bands,demonstrated
R8995 T16505 T16502 prep in,demonstrated
R8996 T16506 T16510 nummod p65,lanes
R8997 T16507 T16506 cc and,p65
R8998 T16508 T16506 conj p50,p65
R8999 T16509 T16510 punct (,lanes
R9000 T16510 T16505 pobj lanes,in
R9001 T16511 T16510 nummod 3,lanes
R9002 T16512 T16511 cc and,3
R9003 T16513 T16511 conj 4,3
R9004 T16514 T16511 punct ),3
R9005 T16515 T16510 neg not,lanes
R9006 T16516 T16510 prep in,lanes
R9007 T16517 T16516 pobj c-Rel,in
R9008 T16518 T16519 punct (,lane
R9009 T16519 T16517 appos lane,c-Rel
R9010 T16520 T16519 nummod 5,lane
R9011 T16521 T16519 punct ),lane
R9012 T16522 T16502 punct .,demonstrated
R9013 T16523 T16530 prep In,observed
R9014 T16524 T16523 pobj normal,In
R9015 T16525 T16530 nsubjpass PBMC,observed
R9016 T16526 T16528 det the,pattern
R9017 T16527 T16528 amod same,pattern
R9018 T16528 T16525 appos pattern,PBMC
R9019 T16529 T16530 auxpass was,observed
R9020 T16530 T16530 ROOT observed,observed
R9021 T16531 T16530 punct ",",observed
R9022 T16532 T16530 cc but,observed
R9023 T16533 T16534 det the,degree
R9024 T16534 T16542 nsubj degree,was
R9025 T16535 T16534 prep of,degree
R9026 T16536 T16537 amod NF-κB,activation
R9027 T16537 T16535 pobj activation,of
R9028 T16538 T16537 prep by,activation
R9029 T16539 T16542 nsubj anti-CD3,was
R9030 T16540 T16539 cc plus,anti-CD3
R9031 T16541 T16539 conj anti-CD28,anti-CD3
R9032 T16542 T16530 conj was,observed
R9033 T16543 T16544 advmod less,intense
R9034 T16544 T16542 acomp intense,was
R9035 T16545 T16544 prep than,intense
R9036 T16546 T16545 pobj that,than
R9037 T16547 T16546 prep in,that
R9038 T16548 T16549 compound RA,PBMC
R9039 T16549 T16547 pobj PBMC,in
R9040 T16550 T16549 punct (,PBMC
R9041 T16551 T16549 appos Fig.,PBMC
R9042 T16552 T16551 nummod 7b,Fig.
R9043 T16553 T16549 punct ),PBMC
R9044 T16554 T16542 punct .,was
R9045 T16555 T16556 aux To,confirm
R9046 T16556 T16566 advcl confirm,performed
R9047 T16557 T16558 det the,link
R9048 T16558 T16556 dobj link,confirm
R9049 T16559 T16558 prep between,link
R9050 T16560 T16561 amod PI3K,activity
R9051 T16561 T16559 pobj activity,between
R9052 T16562 T16561 cc and,activity
R9053 T16563 T16561 conj NF-κB,activity
R9054 T16564 T16566 punct ",",performed
R9055 T16565 T16566 nsubj we,performed
R9056 T16566 T16566 ROOT performed,performed
R9057 T16567 T16566 dobj EMSA,performed
R9058 T16568 T16569 aux to,determine
R9059 T16569 T16566 advcl determine,performed
R9060 T16570 T16573 det the,activity
R9061 T16571 T16573 amod NF-κB,activity
R9062 T16572 T16573 amod binding,activity
R9063 T16573 T16569 dobj activity,determine
R9064 T16574 T16569 prep after,determine
R9065 T16575 T16574 pobj treatment,after
R9066 T16576 T16575 prep with,treatment
R9067 T16577 T16578 det both,LY294002
R9068 T16578 T16576 pobj LY294002,with
R9069 T16579 T16578 cc and,LY294002
R9070 T16580 T16578 conj PDTC,LY294002
R9071 T16581 T16566 punct .,performed
R9072 T16582 T16583 preconj Both,agents
R9073 T16583 T16584 nsubj agents,block
R9074 T16584 T16584 ROOT block,block
R9075 T16585 T16587 nmod NF-κB,activity
R9076 T16586 T16587 amod DNA-binding,activity
R9077 T16587 T16584 dobj activity,block
R9078 T16588 T16587 prep in,activity
R9079 T16589 T16591 det the,promoter
R9080 T16590 T16591 compound IL-17,promoter
R9081 T16591 T16588 pobj promoter,in
R9082 T16592 T16584 punct (,block
R9083 T16593 T16584 npadvmod Fig.,block
R9084 T16594 T16593 nummod 7c,Fig.
R9085 T16595 T16584 punct ),block
R9086 T16596 T16584 punct .,block
R9087 T16597 T16598 amod Western,blotting
R9088 T16598 T16601 nsubj blotting,showed
R9089 T16599 T16598 prep for,blotting
R9090 T16600 T16601 nsubj IκB-α,showed
R9091 T16601 T16601 ROOT showed,showed
R9092 T16602 T16601 dobj inhibition,showed
R9093 T16603 T16602 prep of,inhibition
R9094 T16604 T16603 pobj degradation,of
R9095 T16605 T16604 prep of,degradation
R9096 T16606 T16605 pobj IκB-α,of
R9097 T16607 T16601 prep by,showed
R9098 T16608 T16607 pobj LY294002,by
R9099 T16609 T16608 cc and,LY294002
R9100 T16610 T16608 conj PDTC,LY294002
R9101 T16611 T16601 prep at,showed
R9102 T16612 T16614 det the,time
R9103 T16613 T16614 amod same,time
R9104 T16614 T16611 pobj time,at
R9105 T16615 T16601 punct (,showed
R9106 T16616 T16601 dobj Fig.,showed
R9107 T16617 T16616 nummod 7c,Fig.
R9108 T16618 T16616 punct ),Fig.
R9109 T16619 T16601 punct .,showed
R9110 T16620 T16628 prep In,activated
R9111 T16621 T16620 pobj contrast,In
R9112 T16622 T16628 punct ",",activated
R9113 T16623 T16625 det the,pathway
R9114 T16624 T16625 compound AP-1,pathway
R9115 T16625 T16628 nsubjpass pathway,activated
R9116 T16626 T16628 auxpass was,activated
R9117 T16627 T16628 neg not,activated
R9118 T16628 T16628 ROOT activated,activated
R9119 T16629 T16628 agent by,activated
R9120 T16630 T16629 pobj stimulation,by
R9121 T16631 T16628 prep with,activated
R9122 T16632 T16636 amod anti-CD3,data
R9123 T16633 T16632 cc plus,anti-CD3
R9124 T16634 T16632 conj anti-CD28,anti-CD3
R9125 T16635 T16636 punct (,data
R9126 T16636 T16631 pobj data,with
R9127 T16637 T16638 neg not,shown
R9128 T16638 T16636 acl shown,data
R9129 T16639 T16636 punct ),data
R9130 T16640 T16628 punct ",",activated
R9131 T16641 T16628 advcl demonstrating,activated
R9132 T16642 T16644 mark that,is
R9133 T16643 T16644 nsubj NF-κB,is
R9134 T16644 T16641 ccomp is,demonstrating
R9135 T16645 T16649 det the,pathway
R9136 T16646 T16649 amod main,pathway
R9137 T16647 T16649 amod intracellular,pathway
R9138 T16648 T16649 amod signaling,pathway
R9139 T16649 T16644 attr pathway,is
R9140 T16650 T16649 prep in,pathway
R9141 T16651 T16652 amod IL-17,production
R9142 T16652 T16650 pobj production,in
R9143 T16653 T16649 prep by,pathway
R9144 T16654 T16655 amod activated,PBMC
R9145 T16655 T16653 pobj PBMC,by
R9146 T16656 T16649 prep from,pathway
R9147 T16657 T16656 pobj patients,from
R9148 T16658 T16649 prep with,pathway
R9149 T16659 T16658 pobj RA,with
R9150 T16660 T16628 punct .,activated

bionlp-st-ge-2016-test-tees

Id Subject Object Predicate Lexical cue
T16257 1232-1237 Protein denotes NF-κB
T16256 1185-1194 Protein denotes anti-CD28
T16255 1171-1179 Protein denotes anti-CD3
T16254 1120-1124 Protein denotes AP-1
T16253 1019-1029 Negative_regulation denotes inhibition
T16252 1033-1044 Protein_catabolism denotes degradation
T16251 1093-1100 Protein denotes Fig. 7c
T16250 1048-1053 Protein denotes IκB-α
T16249 1006-1011 Protein denotes IκB-α
T16248 919-924 Negative_regulation denotes block
T16247 919-924 Negative_regulation denotes block
T16246 975-982 Protein denotes Fig. 7c
T16245 959-973 Protein denotes IL-17 promoter
T16241 797-802 Protein denotes NF-κB
T16240 779-783 Protein denotes PI3K
T16239 711-718 Binding denotes intense
T16238 664-674 Positive_regulation denotes activation
T16237 664-674 Positive_regulation denotes activation
T16236 741-748 Protein denotes Fig. 7b
T16235 732-739 Protein denotes RA PBMC
T16234 692-701 Protein denotes anti-CD28
T16233 678-686 Protein denotes anti-CD3
T16232 658-663 Protein denotes NF-κB
T16231 551-554 Protein denotes p50
T16230 543-546 Protein denotes p65
T16229 402-411 Positive_regulation denotes increased
T16228 402-411 Positive_regulation denotes increased
T16227 412-419 Binding denotes binding
T16226 412-419 Binding denotes binding
T16225 340-350 Positive_regulation denotes stimulated
T16224 340-350 Positive_regulation denotes stimulated
T16223 432-447 Protein denotes IL-17 promoters
T16222 423-428 Protein denotes NF-κB
T16221 370-379 Protein denotes anti-CD28
T16220 356-364 Protein denotes anti-CD3
T16219 332-339 Protein denotes RA PBMC
T16218 301-304 Protein denotes Fig
T16217 148-156 Positive_regulation denotes inducing
T16216 163-173 Gene_expression denotes expression
T16215 282-287 Protein denotes IL-17
T16214 238-261 Protein denotes NF-κB recognition sites
T16213 157-162 Protein denotes IL-17
T16212 121-126 Protein denotes IL-15
T16211 113-116 Protein denotes PHA
T16210 97-111 Protein denotes concanavalin A
T16209 86-95 Protein denotes anti-CD28
T16208 72-80 Protein denotes anti-CD3
T16244 925-930 Protein denotes NF-κB
T16243 845-852 Binding denotes binding
T16242 839-844 Protein denotes NF-κB
R8840 T16213 T16216 themeOf IL-17,expression
R8841 T16216 T16217 themeOf expression,inducing
R8842 T16219 T16224 themeOf RA PBMC,stimulated
R8843 T16220 T16225 themeOf anti-CD3,stimulated
R8844 T16221 T16224 causeOf anti-CD28,stimulated
R8845 T16221 T16225 causeOf anti-CD28,stimulated
R8846 T16222 T16226 themeOf NF-κB,binding
R8847 T16222 T16227 themeOf NF-κB,binding
R8848 T16223 T16227 themeOf IL-17 promoters,binding
R8849 T16226 T16228 themeOf binding,increased
R8850 T16227 T16229 themeOf binding,increased
R8851 T16232 T16237 themeOf NF-κB,activation
R8852 T16232 T16238 themeOf NF-κB,activation
R8853 T16233 T16237 causeOf anti-CD3,activation
R8854 T16234 T16238 causeOf anti-CD28,activation
R8855 T16235 T16239 themeOf RA PBMC,intense
R8856 T16242 T16243 themeOf NF-κB,binding
R8857 T16245 T16247 themeOf IL-17 promoter,block
R8858 T16246 T16248 themeOf Fig. 7c,block
R8859 T16250 T16252 themeOf IκB-α,degradation
R8860 T16252 T16253 themeOf degradation,inhibition

testone

Id Subject Object Predicate Lexical cue
T15531 1305-1314 Positive_regulation denotes activated
T15530 1291-1301 Gene_expression denotes production
T15529 1033-1044 Protein_catabolism denotes degradation
T15528 1019-1029 Negative_regulation denotes inhibition
T15527 935-942 Binding denotes binding
T15526 919-924 Negative_regulation denotes block
T15525 845-852 Binding denotes binding
T15524 412-419 Binding denotes binding
T15523 402-411 Positive_regulation denotes increased
T15522 163-173 Gene_expression denotes expression
T15521 148-156 Positive_regulation denotes inducing
T15520 132-143 Regulation denotes responsible
T15519 1285-1290 Protein denotes IL-17
T15518 1190-1194 Protein denotes CD28
T15517 1120-1124 Protein denotes AP-1
T15516 1048-1053 Protein denotes IκB-α
T15515 1006-1011 Protein denotes IκB-α
T15514 959-964 Protein denotes IL-17
T15513 697-701 Protein denotes CD28
T15512 578-583 Protein denotes c-Rel
T15511 551-554 Protein denotes p50
T15510 543-546 Protein denotes p65
T15509 432-437 Protein denotes IL-17
T15508 375-379 Protein denotes CD28
T15507 282-287 Protein denotes IL-17
T15506 157-162 Protein denotes IL-17
T15505 121-126 Protein denotes IL-15
T15504 113-116 Protein denotes PHA
T15503 91-95 Protein denotes CD28
R8543 T15504 T15521 causeOf PHA,inducing
R8544 T15505 T15521 causeOf IL-15,inducing
R8545 T15506 T15522 themeOf IL-17,expression
R8546 T15509 T15524 themeOf IL-17,binding
R8547 T15516 T15529 themeOf IκB-α,degradation
R8548 T15519 T15530 themeOf IL-17,production
R8549 T15521 T15520 themeOf inducing,responsible
R8550 T15522 T15521 themeOf expression,inducing
R8551 T15524 T15523 themeOf binding,increased
R8552 T15527 T15526 themeOf binding,block
R8553 T15529 T15528 themeOf degradation,inhibition